60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Tuesday,Weiss Ratings reports.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of 60 Degrees Pharmaceuticals in a report on Friday, March 28th.

60 Degrees Pharmaceuticals Stock Performance

Shares of NASDAQ:SXTP opened at $3.10 on Tuesday. 60 Degrees Pharmaceuticals has a 52-week low of $1.41 and a 52-week high of $35.99. The company has a market capitalization of $4.57 million, a PE ratio of -0.31 and a beta of 3.41. The company has a fifty day moving average of $2.19 and a 200-day moving average of $4.29.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.